Soleno Therapeutics, Inc.
SLNONASDAQHealthcare
$53.01
+$0.00(+0.00%)
Market Cap$2.8B
P/E Ratio—
52W High$90.3199
52W Low$29.43
Soleno Therapeutics, Inc. (SLNO) · Income Statement
Annual, quarterly, or TTM views · SEC 10-K & 10-Q via FMP · adjust period and M/B/T below.
FMP · SLNO · as of 2026-06-08
Financial statements
Revenue · Gross Profit · Net Income
| Breakdown | 2025-12 | 2024-12 | 2023-12 | 2022-12 | 2021-12 |
|---|---|---|---|---|---|
| Revenue | |||||
| Revenue | $0.19B | $0.00B | $0.00B | $0.00B | $0.00B |
| Cost of Revenue | $0.00B | $0.00B | $0.00B | $0.00B | $0.00B |
| Gross Profit | $0.19B | $0.00B | $0.00B | $0.00B | $0.00B |
| Gross Margin %(computed) | 98.58% | — | — | — | — |
| Operating Expenses | |||||
| R&D Expenses | $0.04B | $0.08B | $0.03B | $0.02B | $0.02B |
| G&A Expenses | $0.00B | $0.11B | $0.01B | $0.01B | $0.01B |
| Total Operating Expenses | $0.17B | $0.19B | $0.04B | $0.02B | $0.03B |
| Operating Income | $0.01B | ($0.19B) | ($0.04B) | ($0.02B) | ($0.03B) |
| Operating Margin %(computed) | 7.85% | — | — | — | — |
| Interest Income | $0.02B | $0.01B | $0.00B | $0.00B | $0.00B |
| Interest Expense | $0.01B | $0.00B | $0.00B | $0.00B | $0.00B |
| Income Before Tax | $0.02B | ($0.18B) | ($0.04B) | ($0.02B) | ($0.03B) |
| Income Tax Expense | $0.00B | $0.00B | $0.00B | $0.00B | $0.00B |
| Net Income | $0.02B | ($0.18B) | ($0.04B) | ($0.02B) | ($0.03B) |
| Net Margin %(computed) | 10.97% | — | — | — | — |
| Per Share & EBITDA | |||||
| EPS (Basic) | $0.41 | $-4.38 | $-2.36 | $-2.87 | $-5.81 |
| Wtd Avg Shares | 0.05B | 0.04B | 0.02B | 0.01B | 0.01B |
| EBITDA | $0.03B | ($0.17B) | ($0.04B) | ($0.02B) | ($0.03B) |
| EBITDA Margin %(computed) | 14.91% | — | — | — | — |
Data source: Financial Modeling Prep · Last updated: 2026-06-08 · USD · B
Explore more Soleno Therapeutics, Inc. data
About Soleno Therapeutics, Inc. (SLNO) Income Statement
Soleno Therapeutics, Inc. (SLNO) income statement data is sourced from SEC Form 10-K and 10-Q filings. For fiscal year 2025, SLNO reported revenue of $0.19B, gross profit of $0.19B (gross margin 98.58%), and net income of $0.02B — a net profit margin of 10.97%.
Frequently asked questions
SLNO · 4 questionsSoleno Therapeutics, Inc. (SLNO) reported revenue of $0.19B for 2025, up —% year-over-year.
SLNO revenueSLNO salesannual revenue YoYincome statement
· Source: FMP /stable/income-statement · SEC EDGAR Form 10-K & 10-Q · As of 2026-06-08